Market Research Reports and Industry Reports

Myelodysplastic Syndrome - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Myelodysplastic Syndrome - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2017, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.

Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 14, 70, 56, 3, 21 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 9, 8, 3, 2 and 2 molecules, respectively.

Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).
- The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction 7
Myelodysplastic Syndrome - Overview 8
Myelodysplastic Syndrome - Therapeutics Development 9
Myelodysplastic Syndrome - Therapeutics Assessment 33
Myelodysplastic Syndrome - Companies Involved in Therapeutics Development 53
Myelodysplastic Syndrome - Drug Profiles 101
Myelodysplastic Syndrome - Dormant Projects 922
Myelodysplastic Syndrome - Discontinued Products 927
Myelodysplastic Syndrome - Product Development Milestones 928
Appendix 942

List Of Tables

List of Tables
Number of Products under Development for Myelodysplastic Syndrome, H2 2017 28
Number of Products under Development by Companies, H2 2017 30
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 31
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 32
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 33
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 34
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 35
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 36
Number of Products under Development by Universities/Institutes, H2 2017 37
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 39
Products under Development by Companies, H2 2017 40
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 41
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 42
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 43
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 44
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 45
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 46
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 47
Products under Development by Companies, H2 2017 (Contd..8), H2 2017 48
Products under Development by Companies, H2 2017 (Contd..9), H2 2017 49
Products under Development by Universities/Institutes, H2 2017 50
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 51
Number of Products by Stage and Target, H2 2017 53
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 54
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 55
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 56
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 57
Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 58
Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 59
Number of Products by Stage and Mechanism of Action, H2 2017 61
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 62
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 63
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 64
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 65
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 66
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017 67
Number of Products by Stage and Route of Administration, H2 2017 69
Number of Products by Stage and Molecule Type, H2 2017 71
Myelodysplastic Syndrome - Pipeline by 4SC AG, H2 2017 72
Myelodysplastic Syndrome - Pipeline by AbbVie Inc, H2 2017 73
Myelodysplastic Syndrome - Pipeline by Acceleron Pharma Inc, H2 2017 73
Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals Inc, H2 2017 74
Myelodysplastic Syndrome - Pipeline by Aeglea BioTherapeutics Inc, H2 2017 74
Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals Inc, H2 2017 75
Myelodysplastic Syndrome - Pipeline by Aileron Therapeutics Inc, H2 2017 75
Myelodysplastic Syndrome - Pipeline by AIMM Therapeutics BV, H2 2017 75
Myelodysplastic Syndrome - Pipeline by Altor BioScience Corp, H2 2017 76
Myelodysplastic Syndrome - Pipeline by Amgen Inc, H2 2017 76
Myelodysplastic Syndrome - Pipeline by Apogenix AG, H2 2017 77
Myelodysplastic Syndrome - Pipeline by Aprea AB, H2 2017 77
Myelodysplastic Syndrome - Pipeline by arGEN-X BV, H2 2017 78
Myelodysplastic Syndrome - Pipeline by Arno Therapeutics Inc, H2 2017 78
Myelodysplastic Syndrome - Pipeline by Array BioPharma Inc, H2 2017 78
Myelodysplastic Syndrome - Pipeline by Astex Pharmaceuticals Inc, H2 2017 79
Myelodysplastic Syndrome - Pipeline by AstraZeneca Plc, H2 2017 79
Myelodysplastic Syndrome - Pipeline by Atara Biotherapeutics Inc, H2 2017 80
Myelodysplastic Syndrome - Pipeline by Bayer AG, H2 2017 80
Myelodysplastic Syndrome - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017 81
Myelodysplastic Syndrome - Pipeline by BerGenBio ASA, H2 2017 81
Myelodysplastic Syndrome - Pipeline by Bio-Path Holdings Inc, H2 2017 82
Myelodysplastic Syndrome - Pipeline by BioLineRx Ltd, H2 2017 82
Myelodysplastic Syndrome - Pipeline by BioLite Inc, H2 2017 83
Myelodysplastic Syndrome - Pipeline by Boehringer Ingelheim GmbH, H2 2017 83
Myelodysplastic Syndrome - Pipeline by Boston Biomedical Inc, H2 2017 83
Myelodysplastic Syndrome - Pipeline by Bristol-Myers Squibb Co, H2 2017 84
Myelodysplastic Syndrome - Pipeline by Calithera Biosciences Inc, H2 2017 84
Myelodysplastic Syndrome - Pipeline by Cantex Pharmaceuticals Inc, H2 2017 85
Myelodysplastic Syndrome - Pipeline by Celgene Corp, H2 2017 85
Myelodysplastic Syndrome - Pipeline by Cell Medica Ltd, H2 2017 86
Myelodysplastic Syndrome - Pipeline by Celldex Therapeutics Inc, H2 2017 86
Myelodysplastic Syndrome - Pipeline by Cellectis SA, H2 2017 87
Myelodysplastic Syndrome - Pipeline by Cellerant Therapeutics Inc, H2 2017 87
Myelodysplastic Syndrome - Pipeline by Celyad SA, H2 2017 88
Myelodysplastic Syndrome - Pipeline by CrystalGenomics Inc, H2 2017 88
Myelodysplastic Syndrome - Pipeline by CTI BioPharma Corp, H2 2017 89
Myelodysplastic Syndrome - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017 89
Myelodysplastic Syndrome - Pipeline by Daiichi Sankyo Co Ltd, H2 2017 90
Myelodysplastic Syndrome - Pipeline by Deciphera Pharmaceuticals LLC, H2 2017 90
Myelodysplastic Syndrome - Pipeline by Eisai Co Ltd, H2 2017 91
Myelodysplastic Syndrome - Pipeline by Eli Lilly and Co, H2 2017 91
Myelodysplastic Syndrome - Pipeline by Epizyme Inc, H2 2017 92
Myelodysplastic Syndrome - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 92
Myelodysplastic Syndrome - Pipeline by Fate Therapeutics Inc, H2 2017 93
Myelodysplastic Syndrome - Pipeline by FibroGen Inc, H2 2017 93
Myelodysplastic Syndrome - Pipeline by Forma Therapeutics Inc, H2 2017 93
Myelodysplastic Syndrome - Pipeline by Fortress Biotech Inc, H2 2017 94
Myelodysplastic Syndrome - Pipeline by Forty Seven Inc, H2 2017 94
Myelodysplastic Syndrome - Pipeline by Fujifilm Holdings Corporation, H2 2017 95
Myelodysplastic Syndrome - Pipeline by Gamida Cell Ltd, H2 2017 95
Myelodysplastic Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2017 96
Myelodysplastic Syndrome - Pipeline by H3 Biomedicine Inc, H2 2017 96
Myelodysplastic Syndrome - Pipeline by Humanigen Inc, H2 2017 97
Myelodysplastic Syndrome - Pipeline by IGF Oncology LLC, H2 2017 97
Myelodysplastic Syndrome - Pipeline by Immune System Key Ltd, H2 2017 97
Myelodysplastic Syndrome - Pipeline by ImmunoGen Inc, H2 2017 98
Myelodysplastic Syndrome - Pipeline by Incyte Corp, H2 2017 98
Myelodysplastic Syndrome - Pipeline by Io Therapeutics Inc, H2 2017 99
Myelodysplastic Syndrome - Pipeline by Jazz Pharmaceuticals Plc, H2 2017 99
Myelodysplastic Syndrome - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2017 100
Myelodysplastic Syndrome - Pipeline by Johnson & Johnson, H2 2017 100
Myelodysplastic Syndrome - Pipeline by JW Pharmaceutical Corp, H2 2017 101
Myelodysplastic Syndrome - Pipeline by Kainos Medicine Inc, H2 2017 101
Myelodysplastic Syndrome - Pipeline by Karyopharm Therapeutics Inc, H2 2017 102
Myelodysplastic Syndrome - Pipeline by Kiadis Pharma NV, H2 2017 102
Myelodysplastic Syndrome - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 103
Myelodysplastic Syndrome - Pipeline by La Jolla Pharmaceutical Company, H2 2017 103
Myelodysplastic Syndrome - Pipeline by Les Laboratoires Servier SAS, H2 2017 103
Myelodysplastic Syndrome - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017 104
Myelodysplastic Syndrome - Pipeline by MacroGenics Inc, H2 2017 104
Myelodysplastic Syndrome - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017 105
Myelodysplastic Syndrome - Pipeline by Mateon Therapeutics Inc, H2 2017 105
Myelodysplastic Syndrome - Pipeline by medac GmbH, H2 2017 106
Myelodysplastic Syndrome - Pipeline by MediGene AG, H2 2017 106
Myelodysplastic Syndrome - Pipeline by MedImmune LLC, H2 2017 107
Myelodysplastic Syndrome - Pipeline by Medivir AB, H2 2017 107
Myelodysplastic Syndrome - Pipeline by MEI Pharma Inc, H2 2017 108
Myelodysplastic Syndrome - Pipeline by Merck & Co Inc, H2 2017 108
Myelodysplastic Syndrome - Pipeline by Merus NV, H2 2017 109
Myelodysplastic Syndrome - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 109
Myelodysplastic Syndrome - Pipeline by Mirati Therapeutics Inc, H2 2017 109
Myelodysplastic Syndrome - Pipeline by Novartis AG, H2 2017 110
Myelodysplastic Syndrome - Pipeline by Onconova Therapeutics Inc, H2 2017 111
Myelodysplastic Syndrome - Pipeline by OncoTherapy Science Inc, H2 2017 111
Myelodysplastic Syndrome - Pipeline by Opsona Therapeutics Ltd, H2 2017 111
Myelodysplastic Syndrome - Pipeline by Pfizer Inc, H2 2017 112
Myelodysplastic Syndrome - Pipeline by Pharma Mar SA, H2 2017 112
Myelodysplastic Syndrome - Pipeline by Plexxikon Inc, H2 2017 113
Myelodysplastic Syndrome - Pipeline by Protagonist Therapeutics Inc, H2 2017 113
Myelodysplastic Syndrome - Pipeline by Rafael Pharmaceuticals Inc, H2 2017 114
Myelodysplastic Syndrome - Pipeline by Rich Pharmaceuticals Inc, H2 2017 114
Myelodysplastic Syndrome - Pipeline by Sorrento Therapeutics Inc, H2 2017 114
Myelodysplastic Syndrome - Pipeline by Stemline Therapeutics Inc, H2 2017 115
Myelodysplastic Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 115
Myelodysplastic Syndrome - Pipeline by Sunesis Pharmaceuticals Inc, H2 2017 116
Myelodysplastic Syndrome - Pipeline by Syndax Pharmaceuticals Inc, H2 2017 116
Myelodysplastic Syndrome - Pipeline by Takara Bio Inc, H2 2017 117
Myelodysplastic Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017 117
Myelodysplastic Syndrome - Pipeline by Tolero Pharmaceuticals Inc, H2 2017 118
Myelodysplastic Syndrome - Pipeline by Trillium Therapeutics Inc, H2 2017 118
Myelodysplastic Syndrome - Pipeline by VasGene Therapeutics Inc, H2 2017 119
Myelodysplastic Syndrome - Dormant Projects, H2 2017 941
Myelodysplastic Syndrome - Dormant Projects, H2 2017 (Contd..1), H2 2017 942
Myelodysplastic Syndrome - Dormant Projects, H2 2017 (Contd..2), H2 2017 943
Myelodysplastic Syndrome - Dormant Projects, H2 2017 (Contd..3), H2 2017 944
Myelodysplastic Syndrome - Dormant Projects, H2 2017 (Contd..4), H2 2017 945
Myelodysplastic Syndrome - Discontinued Products, H2 2017 946

United States Myelodysplastic Syndrome (MDS) Therapeutics Market Report 2017

In this report, the United States Myelodysplastic Syndrome (MDS) Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end

USD 3800View Report

Myelodysplastic Syndrome - Pipeline Review, H2 2017

Myelodysplastic Syndrome - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2017, provides an overview of the Myelodysplastic Syndrome

USD 2000View Report

United States Myelodysplastic Syndrome (MDS) Therapeutics Market Report 2017

In this report, the United States Myelodysplastic Syndrome (MDS) Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end

USD 3800View Report

EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2026

EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2026Irritable bowel syndrome (IBS) is a chronic, relapsing gastrointestinal (GI) disorder that is characterized by abdominal discomfort or pain, bloating, and

USD 3995View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


+91 9987 2952 42

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Nov 2017
No. of Pages :962
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube